Clinical Trials Sponsored by North China Pharmaceutical Group Corporation

Total 336 results

North China Pharmaceutical Group Corporation

Completed

Efficacy and Safety Study of Shenwu Capsule

Mild Cognitive Impairment

China
Peking Union Medical College Hospital
North China Pharmaceutical Group Corporation

Not yet recruiting

Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis

Lupus Nephritis | Immunosuppression | Effect of Drug
Chinese SLE Treatment And Research Group
Beijing Municipal Science & Technology Commission; North China Pharmaceutical...

Recruiting

Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus (SIRIUS)

Systemic Lupus Erythematosus

China
Peking Union Medical College Hospital
North-China Pharmaceutical Company, China

Unknown

The Efficacy and Safety of Sirolimus for Plastic Bronchitis

Plastic Bronchitis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Hemophilia A

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Study of TQH2929 in Healthy Adult Subjects

Psoriasis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.

Sinusitis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Hematological Tumors

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Terminated

Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma

Advanced High-grade Sarcoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects.

Diabetes Mellitus, Type 2

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

TQB3909 Tablets in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Not yet recruiting

Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB2916 Injection in Patients With Advanced Malignant Tumors

Advanced Tumors

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Terminated

A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma

Pancreatic Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers

Psoriasis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial Evaluating the Safety of the TQB2103 for Injection

Advanced Malignant Neoplasm

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

A Study of TQH2722 Injection to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Immunogenicity in Healthy Adult Subjects

Atopic Dermatitis

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of the TQB2930 Injection in Patients With Advanced Cancers

Advanced Cancers

China
Chia Tai Tianqing Pharmaceutical Group Nanjing...

Recruiting

Clinical Trial of the TQB2928 Injection in Patients With Advanced Cancers

Advanced Cancer

China
Wuhan Union Hospital, China
CSPC Pharmaceutical Group Limited

Recruiting

Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies

B-cell Acute Lymphoblastic Leukemia | B-cell Lymphoma Refractory

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)

Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy

Hematologic Malignancy

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets

Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.

Biliary Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).

Advanced Hepatocellular Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2223 Injection in Combination With Penpulimab in Patients With Advanced Cancers

Advanced Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.

Hepatocellular Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

To Evaluate the Efficacy and Safety of TQB3728 Tablets in Sequential Maintenance of TQB2450 Injection Therapy in Patients After Sequential or Concurrent Chemoradiation for Locally Advanced Non-small Cell Lung Cancer.

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Rheumatoid Arthritis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Squamous Cell Carcinoma of the Head and Neck | Metastatic Squamous Cell Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Study of Polyglycan Superparamagnetic Ferric Oxide Injection on Cardiovascular Magnetic Resonance Imaging

Chronic Kidney Diseases | Magnetic Resonance Imaging

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects

Multiple Myeloma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Trial of TQB2618 Injection Combined With TQB2450 Injection in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB2618 Injection Combined With Penpulimab Injection in the Treatment of Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.

Severe Asthma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Phase I Clinical Trial of TQB3915 Tablets in Subjects With Advanced Malignant Solid Tumors

Advanced Malignant Tumor

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail

HR-positive,HER2-negative in Advanced Breast Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Advanced Non-squamous Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

To Evaluate the Pharmacokinetic Effects of TQD3606 for Injection in Healthy Adult Subjects

Infections

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

Chronic Obstructive Pulmonary Disease (COPD)

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors

Advanced Malignant Tumors

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of TQ-B3234 in Patients With Type I Neurofibromatosis

Type I Neurofibromatosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Study to Compare the Efficacy and Safety of AK105 Plus Anlotinib and Capecitabine/Oxaliplatin (CapeOx) , Anlotinib Plus CapeOx, Bevacizumab Plus CapeOx

Unresectable Metastatic Colorectal Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQC3721 Suspension for Inhalation

Chronic Obstructive Pulmonary Disease

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Moderate and High Risk Myelofibrosis

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Study of TQB3820 in Patients With Hematological Malignancies

Hematological Malignancies

China

Clinical Trials Sponsored by North China Pharmaceutical Group Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations